Remedent, Inc.
REMI · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $986 | $864 | $1,408 | $1,030 |
| % Growth | 14.2% | -38.6% | 36.7% | – |
| Cost of Goods Sold | $383 | $358 | $361 | $451 |
| Gross Profit | $603 | $506 | $1,047 | $579 |
| % Margin | 61.2% | 58.5% | 74.4% | 56.2% |
| R&D Expenses | $0 | $0 | $15 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $726 | $789 | $715 | $611 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $726 | $789 | $729 | $611 |
| Operating Income | -$123 | -$283 | $317 | -$32 |
| % Margin | -12.5% | -32.8% | 22.6% | -3.1% |
| Other Income/Exp. Net | -$112 | -$1,188 | -$507 | -$109 |
| Pre-Tax Income | -$235 | -$1,473 | -$190 | -$141 |
| Tax Expense | $17 | $18 | $23 | $3 |
| Net Income | -$274 | -$1,495 | -$257 | -$163 |
| % Margin | -27.8% | -173% | -18.3% | -15.8% |
| EPS | -0.014 | -0.075 | -0.013 | -0.008 |
| % Growth | 81.7% | -479.8% | -57.3% | – |
| EPS Diluted | -0.014 | -0.075 | -0.013 | -0.008 |
| Weighted Avg Shares Out | 19,996 | 19,996 | 19,996 | 19,996 |
| Weighted Avg Shares Out Dil | 19,996 | 19,996 | 19,996 | 19,996 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $4 | $7 | $4 |
| Depreciation & Amortization | $20 | $25 | $28 | $36 |
| EBITDA | -$215 | -$1,443 | -$154 | -$102 |
| % Margin | -21.8% | -167.1% | -10.9% | -9.9% |